Event driven interest in Medtronic stock

Medtronic (MDT) is back in focus after reporting its strongest annual revenue growth in a decade, with fourth quarter revenue up 9.9% year over year and cardio sales showing especially strong momentum.

Investors are weighing how this performance, combined with rapid uptake of PulseSelect and the Affera System and a competitively priced Hugo surgical robot, compares with recent share price weakness and cautious margin commentary.

Despite the strong quarter and recent product milestones like the Nellcor pulse oximetry clearance, Medtronic’s share price has fallen 17.4% year to date and the 5 year total shareholder return is down 26.39%. This suggests long term holders have seen pressure even as near term growth signals build.

If Medtronic’s story has you thinking about how medical technology could reshape care, it may be worth widening your lens and checking out 40 healthcare AI stocks

With Medtronic trading at $79.34, down sharply over 5 years and sitting below some published value estimates, the key question now is whether this weakness offers a mispriced entry point or if the market already reflects future growth.

Most Popular Narrative: 12.2% Undervalued

Medtronic’s most followed narrative pegs fair value at $90.37 per share, compared with the last close of $79.34. This raises clear questions about what assumptions sit behind that gap.

Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.

This narrative leans on moderate growth, steady margins, and a long dividend track record. Curious which assumptions turn that into a double digit discount? The full story connects those moving parts into a single fair value line for Medtronic that you can test against your own view.

Result: Fair Value of $90.37 (UNDERVALUED)

However, Medtronic’s narrative could be challenged if margin pressure persists or if device adoption and diabetes growth lag the expectations embedded in that 12.2% discount.

Next Steps

Seeing both pressure and optimism around Medtronic in one place can be a lot to process, so pull up the numbers, stress test the assumptions, and weigh the balance of 6 key rewards and 1 important warning sign.

Looking for more ideas beyond Medtronic?

If Medtronic has sharpened your focus on quality, do not stop here. Broaden your opportunity set with targeted stock ideas tailored to different portfolio goals.

• Target potential upside by scanning for companies that combine quality fundamentals with discounted prices through the 45 high quality undervalued stocks
• Strengthen your income stream by reviewing stocks that aim to deliver reliable cash returns using the 8 dividend fortresses
• Reduce portfolio stress by focusing on companies with more resilient profiles via the 66 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.